ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Bristol Looks Into Tolerizing Vaccines,
ScripSan Francisco start-up 3T Biosciences came out of stealth mode on 25 August with $40m in new venture capital from a series A round led by Westlake Village BioPartners with participation from Lightsp